Back to 2015 Annual Meeting Display Posters

OBJECTIVE: Suture less aortic valve replacement (AVR) is a new technology for treatment of high risk patients with aortic stenosis. The aim of the study to review our early experience with sutureless aortic valve replacement.
METHODS: Between November 2013 and December 2014, 16 patients underwent sutureless AVR, 13 with the EDWARDS INTUITY rapid deployment valve (Edwards Lifesciences, Irvine, CA, USA) and 3 using Perceval prosthesis in single centre .Their data were analyzed in a prospective manner .Seven patients underwent concomitant coronary artery bypass grafting, 1 underwent concomitant MV repair,1 redo Aortic valve replacement, 1 ministernotomy for AVR , 5 isolated AVR and one case AVR and coronary artery bypass grafting and excision of renal tumour .
RESULTS: The median age was 80.7 years and 8 patients (50%) were male, 3 patients were in NYHA IV and 3 patients needed urgent operations. Median logistic EuroSCORE II was 11.33% and addidtive EUROSCORE 8.4. All valves were successfully implanted with single 30-day mortality(renal tumor).Mean cross clamp time was 57.8 mean bypass time was79.8 . There was no residual aortic paravalvular leak. . At a mean follow-up of 8±4 months (range, 2-16 months), the overall survival was 93%
CONCLUSIONS: Sutureless AVR is a feasible and reproducible procedure. High risk patients ( especially undergoing concomitant surgery )present a higher operative risk, therefore extending the indication for sutureless AVR to this cohort could decrease the risk of this specific population